Samenvatting

National regulatory regimes for supervising ongoing clinical trials are affected by external
challenges, both international, such as harmonization of EU legislation, and national, such
as critical reviews of incidents. This study examines how supervisory bodies dealing with
ongoing trials respond to external challenges of the past two decades and engage in institutional
work to maintain, repair, or improve the Dutch regulatory regime.